Enzyme immunoassay for erythrocyte aldose reductase

• Published in: Clinical chemistry (Baltimore, Md.) Vol. 40; no. 6; pp. 889 - 894
• Main Authors: NISHIMURA, C, HAMADA, Y, TACHIKAWA, T, ISHIKAWA, T, GUI, T, TSUBOUCHI, J, HOTTA, N, TANIMOTO, T, URAKAMI, T
• Format: Conference Proceeding Journal Article
• Language: English
• Published: Washington, DC American Association for Clinical Chemistry 01.06.1994
• Subjects: Adult; Aldehyde Reductase - blood; Aldehyde Reductase - immunology; Animals; Antibodies, Monoclonal; Antibody Specificity; Associated diseases and complications; Biological and medical sciences; Diabetes Mellitus - enzymology; Diabetes. Impaired glucose tolerance; Endocrine pancreas. Apud cells (diseases); Endocrinopathies; Erythrocytes - enzymology; Female; Humans; Immunoenzyme Techniques - statistics & numerical data; Immunoglobulin Fab Fragments; Male; Medical sciences; Mice; Mice, Inbred BALB C; Quality Control; Recombinant Proteins - immunology; Reference Values; Reproducibility of Results; Sensitivity and Specificity; Endocrinopathy; Human; Enzyme; Diabetes mellitus; Red blood cell; Enzyme inhibitor; Exploration; Analysis method; Clinical biology; Aldehyde reductase; Complication; Oxidoreductases; Quantitative analysis
• ISSN: 0009-9147; 1530-8561
• DOI: 10.1093/clinchem/40.6.889

This two-site immunoassay measures erythrocyte aldose reductase by using monoclonal and polyclonal antibodies to recombinant human enzyme. Total incubation time is 2.5 h, and the limit of detection is < 0.05 microgram/L. Analytical recovery tested with blood samples from healthy and diabetic individuals was 101-106%. Average CVs within and between assays were 3.7% and 4.8%, respectively. The enzyme content determined by this system correlated well with the activity of aldose reductase isolated from the same erythrocyte preparations. The amount of erythrocyte aldose reductase per milligram of hemoglobin was higher in women than in men (P < 0.001), but no significant correlation was observed between the amount of enzyme and the age of the individuals. This assay method should provide useful clinical information to optimize administration of aldose reductase inhibitors for effective prevention and treatment of diabetic complications.